J Korean Soc Ther Radiol Oncol.  2009 Sep;27(3):145-152. 10.3857/jkstro.2009.27.3.145.

The Results of Radiotherapy in Locally Advanced, Unresectable Pancreatic Cancer

Affiliations
  • 1Department of Radiation Oncology, Ajou University School of Medicine, Suwon, Korea. shkang@ajou.ac.kr
  • 2Department of Medical Oncology, Ajou University School of Medicine, Suwon, Korea.

Abstract

PURPOSE
We retrospectively studied the outcomes and prognostic factors of patients with locally advanced, unresectable pancreatic cancer who were treated with concurrent chemoradiotherapy (CCRT) or radiotherapy only.
MATERIALS AND METHODS
Fifty-one patients with locally advanced, unresectable pancreatic cancer (stage IIA~III) who recevied radiotherapy (> or =30 Gy) between January 1994 and August 2008 were reviewed retrospectively. The median radiation dose was 39 Gy. Chemotherapy consisted of gemcitabine, cisplatin, or 5-FU alone or in various combinations, and was administered concurrently with radiotherapy in 38 patients.
RESULTS
The follow-up period ranged from 2~40 months (median, 8 months). The median survival, and the 1- and 2-year overall survival (OS) rates were 7 months, 15.7%, and 5.9%, respectively. Based on univariate analysis, the baseline CA19-9, performance status, and chemotherapy regimen were significant prognostic factors. The median survival was 8 months for CCRT, and 6 months for radiotherapy alone. The patients treated with gemcitabine-containing regimens had longer survival (median, 10 months) than the patients treated with radiotherapy alone (p=0.027). Twenty-three patients were available to evaluate the patterns of failure. Distant metastases (DM) occured in 18 patients and regional recurrences were demonstrated in 4 patients. Local progression developed in 14 patients. We analyzed the association between the time-to-DM and the baseline CA19-9 levels for 18 evaluable patients. The median time-to-DM was 20 months for patients with normal baseline CA19-9 levels and 2 months for patients with baseline CA19-9 levels > or =200 U/ml.
CONCLUSION
CCRT with gemcitabine-based regimens was effective in improving OS in patients with locally advanced, unresectable pancreatic cancer. We suggest that the baseline CA19-9 level is valuable in determining the treatment strategy for patients with locally advanced, unresectable pancreatic cancer.

Keyword

Pancreatic cancer; Concurrent chemoradiotherapy; Radiotherapy; CA19-9

MeSH Terms

Chemoradiotherapy
Cisplatin
Deoxycytidine
Fluorouracil
Follow-Up Studies
Humans
Neoplasm Metastasis
Pancreatic Neoplasms
Recurrence
Retrospective Studies
Cisplatin
Deoxycytidine
Fluorouracil
Full Text Links
  • JKSTRO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr